IP Library Granted Patent US 8,076,467
Granted Patent B2
US 8,076,467 · App. 12/578,231 · Granted Dec 13, 2011

Nucleic acid inhibitors of glutamate receptors

Assignees: The Research Foundation of State University of New York; Cornell University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,076,467
App. No.
12/578,231
Granted
Dec 13, 2011
Kind
B2
Abstract

The present invention relates to novel nucleic acid ligands or aptamers that bind to and inhibit the activation of the α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA) subtype of ionotropic glutamate receptors. Also disclosed is a novel combination of technologies, i.e., SELEX and laser pulse photolysis for the selection and screening of aptamers that inhibit receptor function and are useful therefore, in the treatment of diseases associated with excessive activation of ionotropic glutamate receptors.

Claims (13)

1. An isolated nucleic acid that binds to an α-amino-3-hydroxy-5-methyl-4-isoxazole proionate (AMPA) subtype glutamate receptor, wherein said nucleic acid is an RNA and comprises a nucleotide sequence selected from the group consisting of SEQ ID NO.: 1, SEQ ID NO.: 2, SEQ ID NO.: 3, SEQ ID NO.: 4, SEQ ID NO.: 5, SEQ ID NO.: 7, SEQ ID NO.: 8, SEQ ID NO.: 9, SEQ ID NO.: 10 and SEQ ID NO.: 11.

2. The isolated nucleic acid of claim 1 , wherein the nucleic acid contains between 25 and 150 nucleotides.

3. The isolated nucleic acid of claim 1 , wherein the nucleic acid contains between 50 and 100 nucleotides.

4. The isolated nucleic acid of claim 1 , wherein said nucleic acid contains one or more chemically modified nucleotides.

5. The isolated nucleic acid of claim 1 wherein the one or more chemically modified nucleotides has a 2′ fluoro substituent.

6. The isolated nucleic acid of claim 1 wherein the nucleic acid can have one or more secondary structures.

7. The isolated nucleic acid of claim 1 , wherein said nucleic acid inhibits glutamate receptor function.

8. The isolated nucleic acid of claim 1 , wherein said nucleic acid has a K I in the range of 100 to 200 nM.

9. A preparation of the isolated nucleic acids of claim 1 having a single nucleotide sequence, wherein the preparation comprises nucleic acids having more than one secondary structures.

10. The preparation of claim 9 , wherein said isolated nucleic acids contained in said preparation have two secondary structures, both of which are required for inhibition.

11. An isolated DNA that codes for an RNA wherein the RNA comprises a nucleotide sequence selected from the group of SEQ ID NOS.: 1 to 11.

12. A method of inhibiting an AMPA subtype glutamate receptor comprising contacting said receptor with the nucleic acid of claim 1 .

13. A composition comprising a nucleic acid according to claim 1 and a pharmaceutically acceptable carrier.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE NOTICE OF RECORDATION OF ASSIGNMENT PREVIOUSLY RECORDED ON REEL 026510 FRAME 0872. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEES NEED TO BE CORRECTED. Recorded Jan 16, 2012
From: NIU, LI; HUANG, ZHEN; SHI, HUA; LIS, JOHN T.
To: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK; CORNELL UNIVERSITY
Reel/Frame 027536/0946 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2011
From: NIU, LI; SHI, HUA; HUANG, ZHEN; LIS, JOHN T.
To: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
Reel/Frame 026510/0872 →
CONFIRMATORY LICENSE Recorded Jan 14, 2011
From: STATE UNIVERSITY OF NEW YORK AT ALBANY
To: US ARMY, SECRETARY OF THE ARMY
Reel/Frame 025635/0513 →
Continuity (3)
Division 11256726 · Oct 24, 2005
Provisional Application 60621285 · Oct 22, 2004
Related Publication 20100099749A1 · Apr 22, 2010